Stocks in Play

ProMIS Neurosciences

03:15 PM EST - ProMIS Neurosciences : Announced that PMN 310, a monoclonal antibody, has been designated its first lead product for development in Alzheimer's disease. ProMIS Neurosciences shares T.PMN are trading up $0.01 at $0.19.